drugset / Trial / NCT01630057

Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug

NCT01630057

Phase 4 Completed 200 enrolled Eisai Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

An open-label, randomized, multi-centre, superiority study to assess that, in patients who respond to zonisamide added as third drug after failure of a two-drug combination therapy, the triple therapy is superior to the conversion to a double therapy including zonisamide.

Timeline

Start
2009-09
Primary completion
2011-06
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Zonisamide Other / unclassified

Indications